Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
These first real-world data in Korea indicate that emicizumab is effective and safe for pediatric patients with severe hemophilia A without inhibitors.
Authors
- S. Kim (ORCID: https://orcid.org/0009-0003-6073-2406)
- Jeong A Park (ORCID: https://orcid.org/0000-0003-3690-6747)
- Chuhl Joo Lyu (ORCID: https://orcid.org/0000-0001-7124-7818)
- Jung Woo Han (ORCID: https://orcid.org/0000-0001-8936-1205)
- Seung Min Hahn (ORCID: https://orcid.org/0000-0001-9832-6380)
- Young Shil Park (ORCID: https://orcid.org/0000-0002-6643-4245)
- Ji Yoon Kim (ORCID: https://orcid.org/0000-0002-2800-8704)
Institutions
- Yonsei University (KR)
- Kyungpook National University Hospital (KR)
- Kyungpook National University (KR)
- Kyung Hee University Hospital at Gangdong (KR)
- Inha University Hospital (KR)
Publication Details
- Journal
- Blood Research
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1007/s44313-024-00039-1
- Citations
- 2
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91